Navigation Links
Parkinson's Disease Foundation announces research awards totaling $1.2 million
Date:7/1/2010

(July 1, 2010, New York, NY) The Parkinson's Disease Foundation (PDF) is pleased to announce awards totaling $1.2 million for research projects designed to understand the cause(s) of and find a cure for Parkinson's disease (PD).

The awards will support the work of 15 leading scientists and are provided through two key PDF research programs, International Research Grants and Research Fellowship Grants. The first program seeks to fund "high-risk/high-reward" projects that may have a significant impact upon Parkinson's science; the second aims to support the projects of scientists who are in the early stages of their careers.

Stanley Fahn, M.D., PDF's Research Director, commented, "The work of this year's grantees is replete with original ideas for improving our understanding of Parkinson's disease at the most basic levels, and finding new approaches to treating it. We need to be sure that the best talent is attracted to the challenge of solving Parkinson's and helping those who live with it. Funding the promising projects of scientists and young fellows, an area in which PDF leads, is the best way to make this happen."

Among the scientists behind this year's research projects are James Maas, M.D., Ph.D., of the University of California, San Francisco and Leo J. Pallanck, Ph.D., of the University of Washington. With his fellowship, Dr. Maas will be conducting research into the role of dopamine, the neurotransmitter whose loss leads to Parkinson's symptoms. Through his studies into a process called dendritic dopamine release, he hopes to shed light on how the brain controls muscle movement and how the loss of that control develops in the course of Parkinson's.

Dr. Pallanck will use his research grant to investigate the potential of a surprising compound tobacco in saving the neurons lost in Parkinson's disease. He is searching for the exact chemical within tobacco that may protect neurons from the effects of Parkinson's. Dr. Pallanck says this discovery, "in turn, may one day lead to the identification of a potential treatment for Parkinson's."

A full list of 2011 research projects appears below and is available on the PDF website at www.pdf.org/en/results_funded. In fiscal year 2010, PDF contributed $5.5 million towards Parkinson's research programs.

2011 International Research Grants and Fellowships

Ataxin-3-Mediated Regulation of Parkin Stability and Activity
Thomas Durcan, Ph.D.
Montreal Neurological Institute, McGill University

The Role of Alpha-Synuclein in Parkinson's Disease Dementia and Dementia with Lewy Bodies
Sonia George, Ph.D.
University of Minnesota

Telomere Biology in Patients with Incident Parkinson's Disease
Tobias Kurth, M.D., Sc.D., and Robert Y.L. Zee, Ph.D., M.P.H.
Brigham and Women's Hospital

The Regulation of Somatodendritic Dopamine Release
James Maas, M.D., Ph.D.
University of California, San Francisco

Identification of Neuroprotective Factors in Tobacco
Leo J. Pallanck, Ph.D.
University of Washington

Potential Role of DJ-1 in Modulating the VHL/HIF Pathway and its Relevance to PD*
David Park, Ph.D.
University of Ottawa

Mechanism of FADD Recruitment and Activation in Mutant LRRK2-Induced Neurodegeneration*
Hardy Rideout, Ph.D.
Biomedical Research Foundation of the Academy of Athens

Correlating the Structure of Membrane-Bound Alpha-Synuclein with Function and Toxicity
Khurshida Shahidullah, Ph.D.
Weill Cornell Medical College

The Contribution of Dopaminergic System in Pathological Gambling in Parkinson's Disease*
Antonio P. Strafella, M.D., Ph.D., F.R.C.P.C.
Centre for Addiction and Mental Health
Toronto Western Hospital/Institute
University of Toronto

A Functional and Structural Neuroanatomic Analysis of Cognitive Impairment in Parkinson's Disease
Ryan Walsh, M.D., Ph.D.
University of Alabama at Birmingham

LINGO1 and LINGO2 in Parkinson's Disease*
Christian Wider, M.D., and Matthew J. Farrer, Ph.D.
CHUV Lausanne and University of British Columbia

Targeting the CMA Pathway in Cellular Models of Alpha-Synuclein-Induced Neurodegeneration
Maria Xilouri, Ph.D.
Biomedical Research Foundation of the Academy of Athens

Creating a South American Genetics Consortium on Parkinson's Disease*
Cyrus Zabetian, M.D., M.S.
VA Puget Sound Health Care System, Seattle Division
University of Washington


'/>"/>

Contact: Melissa Barry
mbarry@pdf.org
212-923-4700
Parkinson's Disease Foundation
Source:Eurekalert

Related medicine news :

1. Higher testosterone may raise risk of heart disease in elderly men
2. Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities
3. Molecular signatures may aid fight against pediatric liver disease
4. Cancer drug shows promise for treating a wide range of inflammatory diseases
5. Statins May Not Be as Helpful for Those Without Heart Disease
6. Agent Orange exposure linked to Graves disease in Vietnam veterans, UB study finds
7. Mechanism that may trigger degenerative disease identified
8. Ingredient in red wine may prevent some blinding diseases
9. Novel radiotracer shines new light on the brains of Alzheimers disease patients
10. Hallmark Alzheimers disease changes found in retinas of humans and imaged in live animals
11. Antihypertensive drugs may protect against Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came ... contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand ... recently invested $51 million to purchase and renovate the 185,000 square-foot office complex, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: